The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases
- PMID: 28862431
- DOI: 10.1021/acschemneuro.7b00283
The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases
Abstract
Among the diseases affecting the central nervous system (CNS), neurodegenerations attract the interest of both the clinician and the medicinal chemist. The increasing average age of population, the growing number of patients, and the lack of long-term effective remedies push ahead the quest for novel tools against this class of pathologies. We present a review on the state of the art of the molecules (or combination of molecules) of natural origin that are currently under study against two well-defined pathologies: Parkinson's disease (PD) and Huntington's disease (HD). Nowadays, very few tools are available for preventing or counteracting the progression of such diseases. Two major parameters were considered for the preparation of this review: particular attention was reserved to these research works presenting well-defined molecular mechanisms for the studied compounds, and where available, papers reporting in vivo data were preferred. A literature search for peer-reviewed articles using PubMed, Scopus, and Reaxys databases was performed, exploiting different keywords and logical operators: 91 papers were considered (preferentially published after 2015). The review presents a brief overview on the etiology of the studied neurodegenerations and the current treatments, followed by a detailed discussion of the natural and semisynthetic compounds dividing them in different paragraphs considering their several mechanisms of action.
Keywords: CNS; Dementia; Huntington’s disease; Parkinson’s disease; natural products; semisynthetic compounds.
Similar articles
-
Cellular phenotypes as inflammatory mediators in Parkinson's disease: Interventional targets and role of natural products.Biomed Pharmacother. 2018 Oct;106:1052-1062. doi: 10.1016/j.biopha.2018.06.162. Epub 2018 Jul 17. Biomed Pharmacother. 2018. PMID: 30119171 Review.
-
The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.CNS Neurol Disord Drug Targets. 2011 Mar;10(2):239-50. doi: 10.2174/187152711794480483. CNS Neurol Disord Drug Targets. 2011. PMID: 20874702 Review.
-
Mitochondrial superoxide generation induces a parkinsonian phenotype in zebrafish and huntingtin aggregation in human cells.Free Radic Biol Med. 2019 Jan;130:318-327. doi: 10.1016/j.freeradbiomed.2018.10.446. Epub 2018 Oct 31. Free Radic Biol Med. 2019. PMID: 30389496 Free PMC article.
-
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.Lancet. 2014 Aug 9;384(9942):545-55. doi: 10.1016/S0140-6736(14)61010-2. Epub 2014 Jun 18. Lancet. 2014. PMID: 24954676 Review.
-
Protective Effect of Natural Products against Huntington's Disease: An Overview of Scientific Evidence and Understanding Their Mechanism of Action.ACS Chem Neurosci. 2021 Feb 3;12(3):391-418. doi: 10.1021/acschemneuro.0c00824. Epub 2021 Jan 21. ACS Chem Neurosci. 2021. PMID: 33475334 Review.
Cited by
-
Impact of porous nanomaterials on inhibiting protein aggregation behaviour.RSC Adv. 2021 Jan 15;11(6):3354-3362. doi: 10.1039/d0ra10927d. eCollection 2021 Jan 14. RSC Adv. 2021. PMID: 35424305 Free PMC article.
-
Disease-modifying treatment of Parkinson's disease by phytochemicals: targeting multiple pathogenic factors.J Neural Transm (Vienna). 2022 Jun;129(5-6):737-753. doi: 10.1007/s00702-021-02427-8. Epub 2021 Oct 15. J Neural Transm (Vienna). 2022. PMID: 34654977 Review.
-
The medicinal chemistry of Urtica dioica L.: from preliminary evidence to clinical studies supporting its neuroprotective activity.Nat Prod Bioprospect. 2023 May 12;13(1):16. doi: 10.1007/s13659-023-00380-5. Nat Prod Bioprospect. 2023. PMID: 37171512 Free PMC article. Review.
-
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.J Neural Transm (Vienna). 2020 Feb;127(2):131-147. doi: 10.1007/s00702-020-02150-w. Epub 2020 Jan 28. J Neural Transm (Vienna). 2020. PMID: 31993732 Review.
-
Impact of Natural Compounds on Neurodegenerative Disorders: From Preclinical to Pharmacotherapeutics.J Clin Med. 2020 Apr 8;9(4):1061. doi: 10.3390/jcm9041061. J Clin Med. 2020. PMID: 32276438 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical